Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review
Why the study?
Do non-vitamin K oral anticoagulants reduce intracranial hemorrhage in patients with atrial fibrillation compared with warfarin?
Population
Patients with atrial fibrillation
Comparison
Non-vitamin K oral anticoagulants including… vs Warfarin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports preferring NOACs over warfarin in AF to reduce ICH risk; confirms consistent benefit across large randomized trials.
Structured PICO
Do non-vitamin K oral anticoagulants reduce intracranial hemorrhage in patients with atrial fibrillation compared with warfarin?
P
Population
Patients with atrial fibrillation
I
Intervention
Non-vitamin K oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban
C
Comparator
Warfarin
O
Outcome
Intracranial hemorrhage (ICH)safety
This review highlights that NOACs significantly reduce the risk of intracranial hemorrhage compared to warfarin in patients with atrial fibrillation.
Cite This Study
Arbit et al. (2015) studied this question.